OSCR Quantitative Stock Analysis

Validea's guru fundamental report indicates Oscar Health Inc (OSCR), a mid-cap growth stock in the Insurance (Accident & Health) sector, rates 60% using its Kenneth Fisher-based Price/Sales Investor model. While OSCR passes criteria such as Price/Sales and Free Cash Per Share, it fails on Long-Term EPS Growth Rate and Three Year Average Net Profit Margin, resulting in a score below the 80% threshold typically indicating 'some interest' from the strategy.

Analysis

Oscar Health Inc. (OSCR), a mid-cap growth stock within the health insurance industry, receives a reserved assessment from Validea's fundamental analysis, scoring 60% on the Kenneth Fisher-inspired Price/Sales Investor model. This score falls short of the 80% threshold that typically signals moderate interest from the strategy, indicating a mixed fundamental picture. The company demonstrates strength in specific value and cash flow metrics, passing criteria for its Price/Sales Ratio, Price/Research Ratio, and Free Cash Per Share. These positive signals suggest the stock may be attractively valued relative to its revenue and maintains healthy cash generation. However, these strengths are counterbalanced by significant weaknesses in core profitability and growth, as OSCR fails on both its Long-Term EPS Growth Rate and its Three-Year Average Net Profit Margin. The failure on these key metrics highlights a lack of sustained earnings growth and historical margin consistency, which are crucial elements for the underlying investment model despite its emphasis on the P/S ratio.

Key Decisions for Investors

• Given the mixed signals, investors should view OSCR as a potential value play that requires further due diligence, as its attractive Price-to-Sales ratio is offset by significant profitability concerns.
• A key risk factor to monitor is the company's inability to establish consistent profitability, so watch for improvements in its three-year average net profit margin and long-term EPS growth in future earnings reports.
• For those considering a position, the positive free cash flow per share is a notable strength, but it may be prudent to wait for evidence of a turnaround in earnings before committing significant capital, as the current 60% score does not represent a strong endorsement from the model.